^
Association details:
| Biomarker: | FH deletion |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) + Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD24-09: Phase II, Multi-center Study of Sintilimab in Combination with Axitinib in Patients with Advanced Fumarate Hydratase-deficient Renal Cell Carcinoma
Published date:
03/31/2023
Excerpt:
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and highly aggressive cancer mainly caused by germline or somatic aberrant of FH gene….Confirmed complete response rate was 15.8% (3/19), ORR was 63.1% (12/19). Disease-controlled rate (DCR) was 89.4% (17/19)....Sintilimab in combination with Axitinib had a manageable safety profile and achieved a promising tumor response rate in patients with advanced FH-RCC.
Trial ID:
Source:
Title:
Phase II multi-center study of sintilimab in combination with axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma.
Published date:
02/13/2023
Excerpt:
...we report the preliminary results of a phase II study investigating the efficacy and safety of sintilimab in combination with axitinib in patients with FH-RCC....Confirmed complete response rate was 15.8% (3/19), ORR was 63.1% (12/19). Disease-controlled rate (DCR) was 89.4% (17/19). The median of progression-free survival (PFS) was not reached, with a high 12-month PFS rate of 72.3%....Sintilimab in combination with Axitinib had a manageable safety profile and achieved a promising tumor response rate in patients with advanced FH-RCC.
DOI:
10.1200/JCO.2023.41.6_suppl.685
Trial ID:
